Principal Consultant at Clinical Finance Consulting (2025-06 – Present)
Clinical Finance Consulting provides independent finance and strategic advisory services to a range of early-stage biotech companies, supporting financial planning, scenario modeling, and operational readiness across clinical development and partnering activities.
- Developed a long-range financial plan (LRP) with Program Management, modeling lifecycle scenarios to guide resource allocation and support strategic portfolio planning and capital allocation decisions
- Produced financial modeling and scenario analyses to evaluate partnering opportunities for an early-stage biotech company
- Strengthened financial controls by improving investigator grant expense recognition and implementing more reliable close and forecasting processes
- Generated Phase III operational and financial projections using Phase II benchmarks to support budget planning and CRO bid evaluation
Director of Finance at Kinevant Sciences (2024-04 – 2025-06)
Kinevant Sciences was a single-asset subsidiary of Roivant Sciences focused on advancing a pulmonary sarcoidosis program. Kinevant concluded operations following Phase 2 outcomes that fell short of primary endpoints.
- Collaborated with internal stakeholders and external vendors to provide monthly clinical accrual calculations and qualitative flux analysis
- Navigated study winddown to ensure efficient use of capital and resolve all outstanding financial liabilities
- Established procedures mapping investigator grant budgets to Electronic Data Capture (EDC) database to ensure accuracy and timeliness of payments to sites
- Supported business development activities including partnerships for existing asset and diligence for in-licensing new assets
Associate Director of Finance at Kinevant Sciences (2022-06 – 2024-03)
- Implemented procure to pay standard operating procedures to ensure all financial liabilities followed a protocol and that vendors were paid on time
- Negotiated contract research organization and contract manufacturing agreements, ultimately reducing costs by $2.5M+ while ensuring cost-effective execution of multiple global clinical trials
- During the company startup phase, established processes of departmental rolling forecasts and continuously improved executive presentations to facilitate strategic financial decisions
- Led budget-versus-actual variance analysis with departmental heads to communicate variances and proactively identify financial risks and opportunities
Global Finance Manager at Kindeva Drug Delivery (2020-05 – 2022-05)
3M Drug Delivery Systems Division was sold to Altaris Capital in May 2020 and Kindeva Drug Delivery was established as a standalone company. Kindeva Drug Delivery is a global contract drug manufacturer specializing in inhaled and transdermal drug delivery devices.
- Oversaw design and implementation of finance modules for Microsoft D365 ERP system implementation
- Managed $25M revolving line of credit, ensuring strategic working capital allocation while minimizing costs
- Supported the annual long-range planning (LRP) process through discounted cash flow (DCF) projections of multiple R&D programs to inform capital allocation
- Partnered with global stakeholders in prioritization of capital expenditure projects
Financial Analyst at 3M (2018-01 – 2020-05)
- Facilitated acquisition diligence and audit inquiries as part of the $650M Drug Delivery division divestiture
- Advised on long-term initiatives to consolidate manufacturing sites and ultimately improve profitability
- Supported sales and marketing teams in maximizing product pricing profitability
Senior Business Advisor at Surescripts (2017-01 – 2017-12)
- Established go-to-market strategy for e-prescribing solutions specific to underserved and capital constrained long-term care institutions
Senior Financial Consultant at OptumHealth (2013-10 – 2017-01)
- Generated ROI analysis of continuous improvement initiatives for population health management products designed to reduce the medical expenditures for Medicare, Medicaid and commercial payers
Senior Financial Analyst at Vertex Pharmaceuticals (2011-01 – 2013-09)
- Supported commercial organization for the blockbuster launch of both Incivek and Kalydeco
